Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease

Thyroid ◽  
2020 ◽  
Author(s):  
Rie Nishio ◽  
Toyoyoshi Uchida ◽  
Luka Suzuki ◽  
Hiroyuki Onose ◽  
Hiromasa Goto ◽  
...  
Keyword(s):  
Radioactive Iodine ◽  
Graves Disease ◽  
Therapeutic Effects ◽  
Radioactive Iodine Therapy ◽  
Short Term

scholarly journals Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves’ disease

2011 ◽  
Vol 34 (5) ◽  
pp. 262 ◽  
Author(s):  
Qing-Yu Dong ◽  
Shou-jie Li ◽  
Guan-Qi Gao ◽  
Xiao-meng Liu ◽  
Wen-xia Li ◽  
...  
Keyword(s):  
Radioactive Iodine ◽  
Dynamic Change ◽  
Strong Association ◽  
Serum Levels ◽  
Control Group ◽  
Thyroid Peroxidase ◽  
Graves Disease ◽  
Radioactive Iodine Therapy ◽  
Short Term ◽  
Pre Treatment

Purpose: To observe the short-term dynamic change in serum CXC chemokine ligand-10 (CXCL10) levels in patients with Graves' disease (GD) before and after iodine therapy and to analyze the relationship between CXCL10 levels and clinical disease indices. Methods: ELISA was used to determine serum levels of CXCL10 in 43 patients with GD shortly before radioiodine therapy and on days six, 14, and 60, post-therapy. Results: Patients with newly diagnosed GD showed significantly higher levels of serum CXCL10 compared with the control group (P < 0.01). The serum CXCL10 level increased slightly on day six after treatment of radioactive iodine (P < 0.01). There was no significant statistical difference in serum CXCL10 levels pre-treatment and on day 14 post-treatment. A significant reduction in serum CXCL10 level was observed on day 60 (P < 0.01). GD patients with exophthalmia showed higher serum CXCL10 level than GD patients without exophthalmia. No correlation was found between levels of CXCL10 and FT3, FT4 or TSH at any time point, but significant positive correlation was shown between thyroid peroxidase antibodies (TPOAb) and CXCL10 (r=0.50, P < 0.01). Conclusion: CXCL10 participates in the early inflammatory response after radioactive iodine therapy in patients with Graves’ disease and shows a strong association with the autoimmune process.

scholarly journals Suppurative Lymphadenitis after Radioactive Iodine Therapy for Graves’ Disease: A Rare Complication?

2019 ◽  
Vol 8 (6) ◽  
pp. 324-327 ◽  
Author(s):  
Shi Hui Junice Wong
Keyword(s):  
Radioactive Iodine ◽  
Rare Complication ◽  
Cervical Lymphadenopathy ◽  
Symptomatic Treatment ◽  
Graves Disease ◽  
Radioactive Iodine Therapy ◽  
Short Term ◽  
Cervical Lymphadenitis ◽  
Incision And Drainage ◽  
Radiation Induced

Background: Radioiodine (RAI) therapy for Graves’ disease is a well-accepted and effective treatment with a good side effect profile. Short-term adverse effects can occasionally include radiation-induced thyroiditis. To my knowledge, cervical lymphadenitis associated with RAI therapy for Graves’ disease has not been reported before. Case Report: A 38-year-old woman initially presented with uncontrolled thyrotoxicosis secondary to Graves’ disease. She subsequently received RAI therapy for her condition. Within a week, she developed painful bilateral cervical lymphadenopathy that progressed to abscess formation requiring incision and drainage. No other causes (neoplastic or infective) were found. Symptomatic treatment was instituted, and within 2 months the lymphadenitis resolved completely. Discussion: RAI therapy for Graves’ disease can sometimes cause radiation-induced thyroiditis but associated cervical lymphadenopathy or lymphadenitis has not been described. This may represent a continuum of the proinflammatory state induced by RAI manifesting as a rare but potentially morbid complication.

Abstract #1116 Radioactive Iodine Therapy for Graves Disease: What Predicts Failure?

2018 ◽  
Vol 24 ◽  
pp. 281-282
Author(s):  
Kalyani Regeti ◽  
Rajinikanth Yatavelli ◽  
Harsha Karanchi ◽  
Binod Pokhrel
Keyword(s):  
Radioactive Iodine ◽  
Graves Disease ◽  
Radioactive Iodine Therapy

Hyperparathyroidism subsequent to radioactive iodine therapy for Graves' disease

Head & Neck ◽  
2021 ◽  
Author(s):  
Richard H. Law ◽  
Daniel L. Quan ◽  
Andrew J. Stefan ◽  
Edward L. Peterson ◽  
Michael C. Singer
Keyword(s):  
Radioactive Iodine ◽  
Graves Disease ◽  
Radioactive Iodine Therapy

scholarly journals Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease

2013 ◽  
Vol 28 (1) ◽  
pp. 61 ◽  
Author(s):  
Sun Hwa Kim ◽  
Hee Young Kim ◽  
Kwang Yoon Jung ◽  
Dong Seop Choi ◽  
Sin Gon Kim
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Anaplastic Thyroid Carcinoma ◽  
Graves Disease ◽  
Radioactive Iodine Therapy

scholarly journals Effect of Single Dose of Radioiodine Therapy on Volume Reduction of Thyroid Gland in Hyperthyroidism

2019 ◽  
Vol 21 (2) ◽  
pp. 87-91
Author(s):  
Shamrukh Khan ◽  
Faridul Alam ◽  
Fatima Begum ◽  
Sadia Sultana ◽  
Zeenat Jabin ◽  
...  
Keyword(s):  
Single Dose ◽  
Thyroid Gland ◽  
Radioactive Iodine ◽  
Volume Reduction ◽  
Radioactive Iodine Therapy ◽  
Short Term ◽  
Hormone Levels ◽  
Toxic Goiter ◽  
Primary Hyperthyroidism ◽  
Hormone Assay

Introduction: Radioactive iodine therapy (RAIT) in patients with hyperthyroidism (HT) causes apoptosis of thyrocytes to bring about restoration of thyroid function. The aim of the study was to find the short term extent of reduction of thyroid gland volume (TGV) by non-invasive quantitative assessment using ultrasound imaging (USG). Patients and Methods: This prospective study was conducted on a group of patients who had received RAIT due to  primary hyperthyroidism at National Institute of Nuclear Medicine & Allied Sciences (NINMAS). Pre-therapy work up included hormone assay and baseline measurement of TGV by US before administration of  appropriate fixed dose RAIT. Short term follow-up with hormone assay and serial measurements of TGV on two occasions were done at three and six months following the RAIT. Observed temporal changes of parameters were analyzed using appropriate statistics. Results: Total 117 patients with primary hyperthyroidism had received RAIT with diagnosis of diffuse toxic goiter in 86 patients, toxic multinodular goiter in 21 cases and single toxic nodular goiter in 10 cases. There was a decline of mean TGV from the baseline level of 24 ml to 14 ml at three months followed by a further decline to 9.1 ml at six months. Thus the volume reduction of thyroid gland was calculated to be 42% at three months and 62% at six months. The volume reduction was observed to be in a correlative trend with the normalization of hormone levels. The proportion of patients who showed persistent hyperthyroidism till the study end point was 23%. Conclusion: Single dose of radioactive iodine therapy resulted in reduction of TGV up to 62% till six months after RAIT while 23% patients showed persistent hyperthyroidism. The correlative trend of volume reduction with normalization of hormone levels indicates potentiality of TGV to emerge as an adjunct to conventional assessment of treatment efficacy following RAIT.   Bangladesh J. Nuclear Med. 21(2): 87-91, July 2018

Sign in / Sign up

Export Citation Format

Share Document